D-Galactose as a vector for prodrug design

Current Topics in Medicinal Chemistry

Volumn 11, Issue 18, 2011, Pages 2288-2298

  Melisi, Daniela ^a   Curcio, Annalisa ^a   Luongo, Elvira ^a   Morelli, Elena ^a   Rimoli, Maria Grazia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cell permeability; Drug targeting; Galactosyl prodrugs; Pharmacokinetic improvement

Indexed keywords

AMINOLEVULINIC ACID; ANTHRAMYCIN; ASIALOGLYCOPROTEIN RECEPTOR; BETA GALACTOSIDE; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOPAMINE; DOXORUBICIN; GALACTOSE; GELDANAMYCIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; KETOROLAC; LOW DENSITY LIPOPROTEIN; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; PACLITAXEL; PRODRUG; PROSTAGLANDIN E1; PROTOPORPHYRIN; SUPEROXIDE DISMUTASE; TOMAYMYCIN; ZIDOVUDINE;

ANALGESIC ACTIVITY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE TARGETING; GLYCOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; KUPFFER CELL; LIVER INJURY; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; REVIEW; SUSTAINED RELEASE PREPARATION; ULCEROGENESIS;

ANIMALS; DRUG CARRIERS; DRUG DESIGN; GALACTOSE; HUMANS; PRODRUGS; TISSUE DISTRIBUTION;

EID: 80052249302     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611797183258     Document Type: Review

References (68)

1. Stahczak, A.; Ferra, A. Prodrugs and Soft Drugs. Pharmacol. Rep., 2006, 58(5), 599-613.
2. Abbott, N. J.; Romero, I. A. Transporting Therapeutics across the Blood-Brain Barrier. Mol. Med. Today, 1996, 2(3), 106-113.
3. Baldwin, S. A. Mammalian passive glucose transporters: members of an ubiquitous family of active and passive transport proteins. Biochim. Biophys. Acta, 1993, 1154, 17-49.
4. Anderson, B. D. Prodrugs for improved CNS delivery. Adv. Drug Deliv. Rev., 1996, 19, 171-202.
5. Dalpiaz, A.; Filosa, R.; de Caprariis, P.; Conte, G.; Bortolotti, F.; Biondi, C; Scatturin, A.; Prasad, P. D.; Pavan, B. Molecular mechanism involved in the transport of a prodrug dopamine glyco-syl conjugate. Int. J. Pharm., 2007, 336(1), 133-139.
6. Gynther, M.; Ropponen, J.; Laine, K.; Leppänen, J.; Haapakoski, P.; Peura, L.; Järvinen, T.; Rautio, J. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indo-methacin prodrugs in rats. J. Med. Chem., 2009, 52(10), 3348-3353.
7. Halmos, T.; Santarromana, M., Antonakis, K.; Scherman, D. Synthesis of glucose-chlorambucil derivatives and their recognition by the human glut1 glucose transporter. Eur. J. Pharmacol, 1996, 318, 477-484.
8. Fernandez, C; Nieto, O.; Rivas, E.; Montenegro, G.; Fontenla, J.A.; Fernandez-Mayoralas, A. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr. Res., 2000, 327, 353-365.
9. Battaglia, G.; La Russa, M.; Bruno, V.; Arenare, L.; Ippolito, R.; Copani, A.; Bonina, F.; Nicoletti, F. Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents. Brain Res., 2000, 860(1-2), 149-156.
10. Bonina, F. P., Arenare, L.; Palagiano, F.; Saija, A.; Nava, F.; Trombetta, D.; de Caprariis, P. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. J. Pharm. Sci., 1999, 88(5), 561-567.
11. Fernández, C; Nieto, O.; Fontenla, J. A.; Rivas, E.; de Ceballos, M. L.; Fernández-Mayoralas, A. Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier glut-1. Org. Biomol. Chem., 2003, 1(5), 767-771.
12. Bonina, F.; Puglia, C; Rimoli, M. G.; Melisi, D.; Boatto, G.; Nieddu, M.; Calignano, A.; La Rana, G.; de Caprariis, P. Glycosyl derivatives of dopamine and l-dopa as anti-parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J. Drug Target, 2003, 11(1), 25-36.
13. Ruocco, L. A., Viggiano, D.; Viggiano, A.; Abignente, E.; Rimoli, M. G.; Melisi, D.; Curcio, A.; Nieddu, M.; Boatto, G.; Carboni, E.; Gironi Carnevale, U. A.; Sadile, A. G. Galactosylated dopamine enters into the brain, blocks the mesocorticolimbic system and modulates activity and scanning time in naples high excitability rats. Neuroscience, 2008, 152(1), 234-244.
14. Ruocco, L. A., Viggiano, D.; Pignatelli, M.; Iannaccone, T.; Rimoli, M. G.; Melisi, D.; Curcio, A.; De Lucia, S.; Carboni, E.; Gironi Carnevale, U. A.; de Caprariis, P.; Sadile, A. G. Galactosilated dopamine increases attention without reducing activity in C57BL/6 mice. Behav. Brain Res., 2008, 187(2), 449-454.
15. Cabib, S.; Puglisi-Allegra, S.; Ventura, R. The contribution of comparative studies in inbred strains of mice to the understanding of the hyperactive phenotype. Behav. Brain Res., 2002, 130, 103-109.
16. Giordano, C; Siniscalco, D.; Melisi, D.; Luongo, L.; Curcio, A.; Secoupova, M.; de Novellis, V.; Palazzo, E.; Marabese, I.; Rimoli, M. G.; Maione, S. The galactosylation of N™-Nitro-L-arginine enhances its anti-nocifensive or anti-allodynic effects by specifically targeting glia in healthy or neuropathic mice. Eur. J. Pharmacol, 2010, 656(1-3), 52-62.
17. Cidad, P., Garcia-Nogales, P.; Almeida, A.; Bolaños, J. P. Expression of Glucose Transporter GLUT3 by Endotoxin in Cultured Rat Astrocytes: the Role of Nitric Oxide. J. Neurochem., 2001, 79(1), 17-24.
18. Loaiza, A.; Porrai, O. H.; Barros, L. F. Glutamate triggers rapid glucose transport stimulation in astrocytes as evidenced by realtime confocal microscopy. J. Neurosci., 2003, 23(19), 7337-7342.
19. Bijsterbosch, M. K.; van de Bilt, H.; van Berkel, T. J. Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem. Pharmacol, 1996, 52(1), 113-121.
20. Fallon, R. J.; Schwartz, A. L. Receptor-mediated delivery of drugs to hepatocytes. Adv. Drug Deliv. Rev., 1989, 4, 49-63.
21. Donati, I.; Gamini, A.; Vetere, A.; Campa, C; Paletti, S. Synthesis, characterization, and preliminary biological study of glycoconju-gates of poly(styrene-co-maleic acid). Biomacromolecules, 2002, 3(4), 805-812.
22. Weigel, P. H.; Yik, J. H. N. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate Receptors. Biochim. Biophys. Acta, 2002, 1572, 341-363.
23. Eisenberg, C; Seta, N.; Appel, M.; Feldmann, G.; Durand, G.; Feger, J. Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations. J. Hepatol, 1991, 13, 305-309.
24. Kuiper, J., Bakkeren, H. F.; Biessen, E. A.; Van Berkel, T. J. Characterization of the interaction of galactose-exposing particles with rat kupffer cells. Biochem. J., 1994, 299, 285-290.
25. Oda, Y.; Yanagisawa, H.; Maruyama, M.; Hattori, K.; Yamanoi, T. Design, synthesis and evaluation of D-galactose-p-cyclodextrin conjugates as drug-carrying molecule. Bioorg. Med. Chem., 2008, 16, 8830-8840.
26. Zhang, T.; Yu, Y. Y.; Li, D.; Peng, R.; Li, Y.; Jiang, Q.; Dai, P.; Gao, R. Synthesis and properties of a novel methoxy poly(ethylene glycol)-modified galactosylated chitosan derivative. J. Mater. Sci: Mater. Med., 2009, 20, 673-680.
27. Wu, D. Q.; Lu, B.; Chang, C; Chen, C. S.; Wang, T.; Zhang, Y. Y.; Cheng, S. I.; Jiang, X. J.; Zhang, X. Z.; Zhuo, R. X. Galactosylated fluorescent labeled micelles as a liver targeting drug carrier. Biomaterials, 2009, 30, 1363-1371.
28. Ohya, Y.; Oue, H.; Nagatomi, K.; Ouchi, T. Design of macromo-lecular prodrug of cisplatin using dextran with branched galactose units as targeting moieties to hepatoma cells. Biomacromolecules, 2001, 2, 927-933.
29. Cho, C. S.; Cho, K. Y.; Park, I. K.; Kim, S. H.; Sasagawa, T.; Uchiyama, M.; Akaike, T. Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(l-lactic acid) nanoparticles coated with galactose-carrying polystyrene. J. Control. Release, 2001, 77, 7-15.
30. Cho, C. S.; Kobayashi, A.; Takei, R.; Ishihara, T.; Maruyama, A., Akaike, T. Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. Biomaterials, 2001, 22, 45-51.
31. Helling, T. S.; Wogahn, B. M.; Olson, S. A.; Evans, L. S.; Reddy, B. R.; VanWay, C. The effect of prostaglandin e1 on liver adenine nucleotides and cytoplasmic enzymes in a porcine model of nor-mothermic hepatic ischemia. Hepatology, 1995, 22(5), 1554-1559.
32. Hashida, M.; Akamatsu, K.; Nishikawa, M.; Yamashita, F.; Taka-kura, Y. Design of polymeric prodrugs of prostaglandin e1 having galactose residue for hepatocyte targeting. J. Control. Release, 1999, 62, 253-262.
33. Fujita, T.; Furitsu, H.; Nishikawa, M.; Takakura, Y.; Sezaki, H.; Hashida, M. Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem. Biophys. Res. Comm., 1992, 189, 191-196.
34. Bijsterbosch, M. K.; Bakkeren, H. F.; Kempen, H. J.; Roelen, H. C; van Boom, J. H.; van Berkel, T. J. A Monogalactosylated cholesterol derivative that specifically induces uptake of ldl by the liver. Arterioscler. Thromb., 1992, 12(10), 1153-1160.
35. Roelen, H. C; Bijsterbosch, M. K.; Bakkeren, H. F.; van Berkel, T. J.; Kempen, H. J.; Buytenhek, M.; van der Marel, G. A.; van Boom, J. H. Water-soluble cholesteryl-containing phosphorothioate monogalactosides: synthesis, properties, and use in lowering blood cholesterol by directing plasma lipoproteins to the liver. J. Med. Chem., 1991, 34(3), 1036-1042.
36. Merwin, J. R.; Noell, G. S.; Thomas, W. L.; Chiou, H. C; DeRome, M. E.; McKee, T. D.; Spitalny, G. L.; Findeis, M. A. Targeted delivery of DNA using YEE(Galnacah)3, a synthetic gly-copeptide ligand for the asialoglycoprotein receptor. Bioconjug. Chem. 1994, 5, 612-621.
37. Perales, J. C; Ferkol, T.; Beegen, H.; Ratnoff, O. D.; Hanson, R. W. Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc. Natl. Acad. Sci. USA, 1994, 91, 4086-4090.
38. Han, J.; Yeom, Y. I. Specific gene transfer mediated by galactosy-lated poly-l-lysine into hepatoma cells. Int. J. Pharm., 2000, 202, 151-160.
39. Matsuda, I.; Konno, H.; Tanaka, T.; Nakamura, S. Antimetastatic effect of hepatotropic liposomal adriamycin on human metastatic liver tumors. Surg. Today, 2001, 31(5),414-420.
40. Nishikawa, M.; Hyoudou, K.; Kobayashi, Y.; Umeyama, Y.; Takakura, Y.; Hashida, M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant Enzymes. J. Control. Release, 2005, 109, 101-107.
41. Shaw, R. J. Glucose metabolism and cancer. Curr. Opin. Cell Biol, 2006, 18(6), 598-608.
42. Ito, S.; Fukusato, T.; Nemoto, T.; Sekihara, H.; Seyama, Y.; Ku-bota, S. Coexpression of glucose transporter 1 and matrix metallo-proteinase-2 in human cancers. J. Natl. Cancer Inst., 2002, 94(14), 1080-1091.
43. Melisi, D.; Rosso, F.; Curcio, A.; Tortora, C; Nieddu, M., Marino, G.; Lettieri, M., Grimaldi, A., Luongo, E., Romano, S.; Romano, M.F.; Boatto, G., Abignente, E. Barbarisi, A.; Rimoli, M. G. Galactosyl derivative of N-Nitro-l-arginine: study of antiproliferative activity on human thyroid follicular carcinoma cells. J. Cell. Physiol. 2009, 221, 440-447.
44. Vallinayagam, R.; Schmitt, F.; Barge, J.; Wagnieres, G.; Wenger, V.; Neier, R.; Juillerat-Jeanneret, L. Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer. Bioconju-gate Chem., 2008, 19, 821-839.
45. Mikuni, K.; Nakanishi, K.; Hara, K.; Hara, K.; Iwatani, W.; Amano, T.; Nakamura, K.; Tsuchiya, Y.; Okumoto, H.; Mandai, T. In vivo antitumor activity of novel water-soluble taxoids. Biol. Pharm. Bull, 2008, 31(6), 1155-1158.
46. Kratz, F.; Muller, I. A.; Ryppa, C; Warnecke, A. Prodrug strategies in anticancer chemotherapy. ChemMedChem, 2008, 3, 20-53.
47. Devalapally, H.; Navath, R.S.; Yenamandra, V.; Akkinepally, R. R.; Devarakonda, R. K. P-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy. Arch. Pharm. Res., 2007, 30(6), 723-732.
48. Devalapally, H.; Rajan, K. S.; Akkinepally, R. R.; Devarakonda, R. K. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev. Ind. Pharm., 2008, 34(8), 789-795.
49. Leenders, R. G. G.; Damen, E. W. P.; Bijsterveld, E. J. A.; Scheeren, H. W.; Houba, P. H. J.; van der Meulen-Muileman, I. H.; Boven E.; Haisma, H. J. Novel anthracycline-spacer-β-glucuronide, -β-glucoside, and -β-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem., 1999, 7, 1597-1610.
50. Arafa, H. M. M. Possible contribution of peta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells. Invest. New Drugs, 2009, 616(1-3), 58-63.
51. Kamal, A.; Tekumalla, V.; Krishnan, A.; Pal-Bhadra, M.; Bhadra, U. Development of Pyrrolo[2,1-c][1,4]benzodiazepine p-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT. ChemMedChem, 2008, 3, 794-802.
52. Thomas, M.; Rivault, F.; Tranoy-Opalinski, I.; Roche, J.; Gesson J.; Papot, S. Synthesis and biological evaluation of the suberoy-lanilide hydroxamic Acid (SAHA) p-glucuronide and p-galactoside for application in selective prodrug chemotherapy. Bioorg. Med. Chem. Lett. 2007, 17, 983-986.
53. Cai, T. B.; Lu, D.; Tang, X.; Zhang, Y.; Landerholm, M.; Wang, P. G. New glycosidase activated nitric oxide donors: glycose and 3-morphorlinosydnonimine conjugates. J. Org. Chem. 2005, 70, 3518-3524.
54. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol, 1995, 36, 305-315.
55. Cheng, H.; Cao, X.; Xian, M.; Fang, L.; Cai, T. B.; Ji, J. J.; Tunac, J. B.; Sun, D.; Wang, P. G. Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. J. Med. Chem., 2005, 48, 645-652.
56. Fang, L.; Battisti, R. F.; Cheng, H.; Reigan, P.; Xin, Y.; Shen, J.; Ross, D.; Chan, K. K.; Martin Jr, E. W.; Wang, P. G.; Sun, D. Enzyme specific activation of benzoquinone ansamycin prodrugs using antibody-β-galactosidase conjugates. J. Med. Chem., 2006, 49(21), 6290-6297.
57. Tietze, L. F.; Herzig, T.; Fecher, A.; Haunert, F.; Schuberth, I. Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy. ChemBio-Chem, 2001, 2, 758-765.
58. Tietze, L. F.; Major, F.; Schuberth, I.; Spiegl, D. A.; Krewer, B.; Maksimenka, K.; Bringmann, G.; Magull, J. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins. Chem. Eur. J., 2007, 13, 4396-4409.
59. Abraham, R.; Aman, N.; von Borstel, R.; Darsley, M.; Kamireddy, B.; Kenten, J.; Morris, G.; Titmas, R. Conjugates of COL-1 monoclonal antibody p-d-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug p-d-galactosyl-5-fluorouridine. Cell. Biophys., 1994, 24-25, 127-133.
60. Melisi, D.; Secondo, A.; Montoro, P.; Piacente, S.; Rimoli, M. G.; Minale, M.; De Caprariis, P.; Annunziato, L. Galactosyl derivatives of l-arginine and d-arginine: synthesis, stability, cell permeation, and nitric oxide production in pituitary GH3 cells. J. Med. Chem., 2006, 49, 4826-4833.
61. Holick, M. F.; Ramanathan, H. Conjugates Comprising an NSAID and Sugar and uses thereof. US. Pat. Apl, 0215487, Sep. 29, 2005.
62. Kauffman, G. L. Jr. Gastric mucus and bicarbonate secretion in relation to mucosal protection. J. Clin. Gastroenterol, 1981, 3(2), 45-50.
63. Srikanta, B. M.; Siddaraju, M. N.; Dharmesh, S. M. A novel phe-nolbound pectic polysaccharide from decalepis hamiltonii with multistep ulcer preventive. World J. Gastroenterol, 2007, 13(39), 5196-5207.
64. Curcio, A.; Sasso, O.; Melisi, D.; Nieddu, M., La Rana, G.; Russo, R.; Gavini, E.; Boatto, G.; Abignente, E.; Malignano, A.; Rimoli, M. G. Galactosyl prodrug of ketorolac: synthesis, stability, and pharmacological and pharmacokinetic evaluations. J. Med. Chem., 2009, 52(12), 3794-3800.
65. Mishra, A.; Veerasamy, R.; Jain, P. K.; Dixit, V. K.; Agrawal, R. K. Synthesis, characterization and pharmacological evaluation of amide prodrugs of ketorolac. Eur. J. Med. Chem., 2008, 43(11), 2464-2472.
66. Vyas, S.; Trivedi, P.; Chaturvedi, S. C. Ketorolac-dextran conjugates synthesis, in vitro and in vivo evaluation. Acta Pharm., 2007, 57, 441-450.
67. Bonina, F., Puglia, C; Rimoli, M. G.; Avallone, L., Abignente, E.; Boatto, G.; Nieddu, M.; Meli, R.; Amorena M.; de Caprariis, P. Synthesis and in vitro chemical and enzymatic stability of glycosyl 3'-azido-3'-deoxythymidine derivatives as potential anti-HIV agents. Eur. J. Pharm. Sci., 2002, 16(3), 167-174.
68. Tiwari, P.; Misra, A. K. Selective removal of anomeric o-acetate groups in carbohydrates using HClO4-SiO2. Tetrahedron Lett, 2006, 47, 3573-3576